Concord Biotech Limited — Others, 15-02-2025: Copy of Newspaper Publication

Total income from operations for Concord Biotech increased to ₹244.22 crore for the quarter ending December 31, 2024, compared to ₹310.18 crore during the previous quarter. Net profit before tax was ₹9.93 crore, with a profit of ₹7.41 crore after tax. The company's total comprehensive income for the period was ₹9.15 crore. On a consolidated basis, total income stood at ₹310.18 crore, with a net profit after tax of ₹9.78 crore. This performance reflects solid operational stability but highlights a decline in income as compared to the previous quarter. Investors might view this as a mixed signal, suggesting some caution.